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Osteosarcoma of the foot is a very rare presentation of a rare tumor entity. In a retrospective analysis, we investigated tumor- and
treatment-related variables and outcome of patients registered in the Cooperative Osteosarcoma Study Group (COSS) database
between January 1980 and April 2016 who suffered from primary high-grade osteosarcoma of the foot. Among the 23 eligible
patients, median age was 32 years (range: 6–58 years), 10 were female, and 13 were male. The tarsus was the most commonly
affected site (n ! 16). Three patients had primary metastases. All patients were operated: 5 underwent primary surgery and 18
received surgery following preoperative chemotherapy. In 21 of the 23 patients, complete surgical remission was achieved. In 4 of
17 patients, a poor response to neoadjuvant chemotherapy was observed in the resected primary tumors. Median follow-up was
4.2 years (range: 0.4–18.5). At the last follow-up, 15 of the 23 patients were alive and 8 had died. Five-year overall and event-free
survival estimates were 64% (standard error (SE) 12%) and 54% (SE 13%), which is similar to that observed for osteosarcoma in
general. Event-free and overall survival correlated with primary metastatic status and completeness of surgery. Our findings show
that high-grade osteosarcoma in the foot has a similar outcome as osteosarcoma of other sites.
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1. Introduction
Bone tumors of the foot have been reported to be rare, and
reported studies are limited to case reports and very few
small cohort studies [1–6]. Of these tumors, 23–26% are
malignant and only 4% represent osteosarcomas, whereas
only 1% of all osteosarcomas occur in the foot [6–8].
To fill the current gap in literature, we evaluated in this
study all patients with an osteosarcoma of the foot registered
by the COSS to identify prognostic factors and to evaluate
similarities and differences in outcome compared to other
osteosarcoma sites.
2. Methods
2.1. Patient Eligibility. The analysis is based on all patients
registered by the Cooperative German-Austrian-Swiss Os-
teosarcoma Study Group (COSS) since 1980 [9–15]. The
study group’s primary focus has generally been on patients
with primary high-grade central osteosarcoma of bone
under 40 years of age, but all other patients in a different age
group or diagnosed with another type of osteosarcoma were
also registered and followed.
All COSS studies were approved by the appropriate
ethics and/or protocol review committee. Before registration
and therapy, informed consent was obtained from all pa-
tients and/or their legal guardians, depending on patients’
age.
This study is based on all patients with a primary,
previously untreated high-grade osteosarcoma of the foot
registered between January 1980 and April 2016 with
a follow-up of at least 3 months.
2.2. Diagnostics. Diagnostic procedures used to define the
extension of the primary tumor included conventional ra-
diography in all studies, whereas computed tomography
(CT) scan and magnetic resonance imaging (MRI) varied
over time. To exclude primary metastases, a chest X-ray and
a 99mTc-methylene-diphosphonate bone scan were con-
ducted, since 1991 a CT scan of the chest was mandatory as
well. Follow-up analyses included X-rays of the chest and
primary tumor site in intervals defined by the appropriate
COSS protocol. In case of systemic metastases at any time
after initial diagnosis, a complete restaging was performed.
2.3. Treatment. Treatment including preoperative (neo-
adjuvant) and postoperative chemotherapy and surgery was
to be performed according to the COSS protocols active at
enrolment [10–13, 15–17]. In brief, all protocols included
varying combinations of high-dose methotrexate with leu-
covorin rescue, doxorubicin, cisplatin, and/or ifosfamide
and sometimes others.
Local therapy was to be performed by surgery during
weeks 9 to 11 of therapy, depending on the employed
protocol. The type of resection was decided by the local
surgeon but it was recommended to attempt wide or radical
resections [18] and, if present, it was also recommended to
completely resect all primary metastases [17].
2.4. DataCollection andDefinition of Variables. All variables
were collected prospectively and evaluated for distribution
within the evaluated patient cohort and for possible cor-
relations with outcome.
Patient age and sex: Self-explanatory.
Tumor site: Tumor site within the foot was classified
by us into one of the three anatomic parts of the foot
(phalanges, metatarsal bones, and tarsus) according to the
specific bone involved.
Tumor size: Absolute tumor volume as measured by
initial imaging.
Primary metastases: Primary systemic dissemination was
assumed whenever metastases other than skip lesions were
detected on initial staging, except when the suspicion was
later excluded by surgery with negative histology. Patients
with a radiologic diagnosis of primary metastases who never
underwent surgery for the suspected metastases were in-
cluded among those with primary dissemination.
Alkaline phosphatase (AP) and lactate dehydrogenase
(LDH): Serum levels of AP and LDH were obtained at initial
diagnosis. Levels were considered as elevated (E) if they
exceeded the upper limit of normal (N) as stated by the local
laboratory.
Symptoms and their duration: Most COSS protocols,
except for those active between 1985 and 1990, included an
assessment of symptom duration. The interval between the
onset of pain and/or tumor-associated swelling and
biopsy/primary operation was counted in days.
Delay of chemotherapy: The lag time from diagnostic
procedure to the first day of chemotherapy. A treatment
delay was arbitrarily defined as an interval of longer than 21
days.
Timing of surgery: Primary surgery was assumed
whenever an attempt to remove the primary lesion had been
performed before the initiation of chemotherapy, whether
this had been done with or without the knowledge of the
correct diagnosis, whereas primary chemotherapy was as-
sumed if the start of chemotherapy had preceded surgery.
Type of local surgery: The surgical procedures were di-
vided into amputation and foot-saving resections as final
solution.
Complete surgical remission (CR): A complete surgical
remission was assumed only when all detectable tumor foci
were removed during first-line therapy. If no complete
surgical remission could be achieved, the day after diagnostic
biopsy was considered the day of the first event.
Tumor response: Response to preoperative chemotherapy
was assessed histologically according to the six-grade scale of
Salzer-Kuntschik et al. A good response was defined as less
than 10% viable tumor residues (response grades 1–3), poor
tumor response in case of more than 10% vital tumor cells
(grade 4–6) [19].
2.5. Statistical Methods. All eligible patients were evaluated
on an intent-to-treat basis. All parameters were investigated
by univariate techniques. The Kaplan–Meier method [20]
was used for survival analysis, and for analysis of the sub-
groups according to the defined variables, the log-rank test
2 Sarcoma
(Mantel-Cox test) or, if appropriate, Breslow’s test (gener-
alized Wilcoxon test) was used for comparisons [21–23].
Overall survival was calculated from the time of diagnostic
biopsy until death. Event-free survival was calculated until
death or first event, whatever occurred first. Patients who
never achieved a complete surgical remission were assumed
to have suffered an event on day one after diagnostic biopsy.
All P values are two-sided, and significant implies
P< 0.05. SPSS version 22.0 (SPSS Inc., Chicago, IL) was used
for statistical calculations.
3. Results
We identified 30 patients registered as having osteosarcomas
of the foot within the COSS database. Seven of these were
excluded from further analyses: five low-grade osteosarco-
mas (three low-grade central and two parosteal), one os-
teosarcoma occurred as a secondary malignancy (following
B-cell lymphoma), and one benign bone lesion originally
misdiagnosed as osteosarcoma, leaving 23 patients with
primary high-grade osteosarcomas for statistical analyses
(Table 1). The diagnosis of osteosarcoma was made or
confirmed by a member of the COSS reference pathology
panel in 19 of 23 eligible patients, while four samples were
seen by local pathologists only. Patients were registered by
18 institutions from three different European countries
(Germany 14, Austria 3, and Switzerland 1).
There were 13 males and ten females, and median age
was 32 years (range: 6–58 years). Among 21 of the 23
patients with information on prediagnostic symptoms,
eight (38%) complained of pain only, two (10%) registered
swelling only, and eleven (52%) reported both, resulting in
a total of 19 (90%) patients with pain and 13 (62%) with
swelling. In 20 of the 23 patients with relevant data
available, the median duration between first symptoms and
diagnostic biopsy was 154 days (range: 21–1940 days).The
patient with the longest prediagnostic interval had received
multiple previous biopsies, with diagnoses ranging from
bone cyst to fibrous dysplasia, prior to the diagnosis of
osteosarcoma.
Localization of the primary tumor was as follows: in two
patients a phalanx (9%), in five patients a metatarsal bone
(21%), and in 16 patients a tarsal bone (70%). Absolute
tumor volume was documented for 10 of the 23 patients,
the median being 31.5 cm3 (range: 3–54 cm3). All tumors
were T1 tumors (<8 cm) according to AJCC staging system
(Table 1).Three patients had evidence of primary metastases:
one had ipsilateral inguinal lymph node involvement and
two suffered from pulmonary metastases.
Among 20 of the 23 patients with appropriate in-
formation, serum alkaline phosphatase (AP) levels at di-
agnosis were normal in 15 (75%) and elevated in five
(25%). Among 19 out of 23 patients with available in-
formation on lactate dehydrogenase (LDH) serum levels at
diagnosis, these were normal in 16 (84%) and elevated in
three (16%).
Eighteen of the 23 patients received preoperative che-
motherapy, while five had primary surgery (three prior
to receiving the correct diagnosis and two thereafter).
The median duration between diagnostic biopsy/primary sur-
gery and start of chemotherapy was 28 days (range: 1–83 days).
Twenty-one of the 23 patients (87%) achieved a mac-
roscopically complete surgical remission of all tumor sites
(Tables 1 and 2). The remaining two were not operated for
pulmonary metastases, one of these had progression of
primary metastases and the other developed metastases
during preoperative chemotherapy. Among the 23 patients
with known surgery of their primary tumor, 19 (83%) re-
ceived only one surgical procedure until obtaining their best
total surgical outcome and 4 (17%) received two surgical
procedure (three patients received amputation after in-
complete primary resection and one patient received
complete resection of pulmonary metastases). In total, 19
patients (83%) underwent amputations and four (17%)
foot-saving resections (Tables 1 and 3). Among these four
patients, three received a resection with wide margins and
one with marginal margins.The patient receiving resection
with marginal margins had primary pulmonary metastases,
which were not operated, and developed a large local
recurrence.
Four of 17 (25%) tumors which were resected following
preoperative chemotherapy and for whom information on
histological response was available responded well to pre-
operative chemotherapy (<10% viable tumor), and thirteen
(75%) responded poorly (Tables 1 and 4).
Twenty-two patients received systemic chemotherapy
for their primary disease; information on the drugs used was
available for 21. Among these, all 21 received doxorubicin,
21 received cisplatin (100%) (two additional carboplatin),
19 ifosfamide (90%), 16 high-dose methotrexate (76%), and
five etoposide (24%) (Table 1).
After a median follow-up of 4.2 years (range: 0.4–18.5
years) for all 23 patients and 4.8 years (range: 0.4–18.45
years) for the 15 survivors, three- and five-year survival
estimates were 84% (standard error (SE) 8.6%) and 64% (SE
12%), respectively (Figure 1). Among the 15 survivors,
thirteen were in first complete remission, one was lost to
follow-up while in first recurrence, and another one was
alive with his third recurrence. Of the eight patients who
died, six suffered from progressive disease (two without ever
having achieved a complete remission, one in first, one in
second, and two after third recurrence), one of a secondary
malignancy (Ewing sarcoma), and one of an unknown cause
during first recurrence (Tables 1 and 5).
Among 21 patients in whom complete surgical remission
was achieved, thirteen remained event free and eight ex-
perienced an event. Among these, five developed lung
metastases (de novo, 1 following complete removal of pri-
mary lung metastases), one de novo ipsilateral inguinal
lymph node metastases, and one a recurrence in the ipsi-
lateral proximal lower leg following complete surgery of
both the primary tumor and primary (inguinal) lymph node
metastases. In addition, one patient died from a secondary
malignancy (Ewing sarcoma) (Table 1).Three- and five-year
event-free survival estimates were 62% (SE 12%) and 54%
(SE 13%), respectively.There was no significant difference in
overall and event-free survival between the first 18 years of
patient recruitment and the second 18 years.
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Event-free survival (EFS) and overall survival (OAS)
correlated with primary metastatic status and best surgical
remission status (Table 6).
4. Discussion
Osteosarcoma of the foot is exceedingly rare, and conse-
quently the available information on patient and tumor
characteristics, optimal management, and outcome is very
limited. Therefore, we decided to investigate the greatest
time span possible (36 years) using the data prospectively
collected by the Cooperative German-Austrian-Swiss Os-
teosarcoma Study Group.We were able to analyze 23 eligible
patients with primary high-grade osteosarcoma of the foot,
which represents one of the largest cohorts of such patients
reported to date.
While recommended diagnostic and therapeutic pro-
cedures have varied to some extent during this prolonged
period, the overall results of osteosarcoma therapy have not
[24–27], so we believe our findings hold true even for today.
Low-grade as well as secondary osteosarcomas were ex-
cluded, as their biology and/or treatment differs from the
more common primary high-grade central osteosarcomas.
Concerning patient-related variables, we observed the
same slight male predominance as known for extremity
osteosarcoma [28], but, similar to others [1, 2], a consider-
ably older median age of 32 years. As in osteosarcoma, in
general [13], pain was the most frequent presenting
symptom.The median duration between first symptoms and
diagnostic biopsy was 154 days (range: 21–1940 days), which
is shorter than that described in other series of osteosar-
comas of the feet [2, 4] but longer than that we have observed
for other extremity osteosarcomas (median: 69 days) [13].
Like others [1, 5], we observed the tarsal bones to be the
most frequently affected site within the foot. In our 23
patient cohort, three had evidence of primary metastases
Table 2: Complete surgical remission in localized and metastatic disease.
Surgical remission Number of patients with localizeddisease
Number of patients with metastatic
disease
Number of all
patients
Number of patients 20 3 23
Complete resection of primary tumor 20 3 23
Complete resection of metastases 0∗ 2 2
Complete surgical remission 19 2 21
One patient with localized disease developed pulmonary metastases during preoperative chemotherapy and did not receive metastasectomy because of
progressive disease.
Table 3: Type of surgery.
Type of surgery Number of patients with localized disease Number of patients with metastatic disease Number of all patients
Amputation 17 2 19
Resection 3 1 4
Table 4: Tumor response to preoperative chemotherapy.
Tumor response Number of patients with localizeddisease
Number of patients with metastatic
disease
Number of all
patients
Good (less than 10% viable tumor cells) 3 1 4
Poor (more than 10% viable tumor cells) 11 2 13
Not applicable (primary surgery) 5 0 5
Not documented 1 0 1
1.0
0.9
0.8
0.7
0.6
0.5
O
AS
 ve
rs
us
 E
FS
0.4
0.3
Figure 1: Overall survival ( ) (95% confidence interval: 0.0–10.8)
and event-free survival ( ) (95% confidence interval: 3.6–14.3) of
the 23 patients with high-grade osteosarcoma of the foot.
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upon imaging, comparable to the situation in osteosarcoma
of other sites [13, 29]. Two had lung metastases and one had
lymph node metastases, the latter being rather unusual for
osteosarcoma [30]. Compared to osteosarcoma in general
[31], fewer patients from our series presented with elevated
alkaline phosphatase levels, probably correlating with their
smaller tumor volumes, while the rate of elevated lactate
dehydrogenase was similar [32].
Table 5: Outcome at the last follow-up.
Outcome Number of patients with localized disease Number of patients with metastatic disease Number of all patients
Died 5 3 8
Alive 15 0 15
Alive CR1 13 0 13
Alive Rec1-LFU 1 0 1
Alive CR3 1 0 1
CR! complete surgical remission (primary tumor and metastases); CR1 ! first complete surgical remission; CR3 ! third complete surgical remission;
Rec. 1! first recurrence; LFU! lost to follow-up.
Table 6: Univariate analysis of overall and event-free survival.
Survival Number of patients Percent
Event-free survival Overall survival
Variable 5 year (%) SE (%) P (log-rank) 5 year (%) SE (%) P (log-rank)
Total 23
Age<32 years (median) 12 52 64 15 0.438 61 15 0.828>32 years 11 48 39 21 67 20
Sex
Male 13 57 44 18 0.791 39 17.5 0.235Female 10 43 63 18 89 10.5
Tumor site
Tarsus 16 70 49 16 0.903 57 15 0.503Other 7 30 71 17 80 18
Tumor size<31.5 cm3 (median) 5 50 80 18 0.786 80 18 0.366>31.5 cm3 5 50 67 27 67 27
Primary metastases
No 20 87 66 13 0.005 78 11 0.008Yes 3 13 0 0 0 0
AP
Normal 15 75 60 16 0.216 57 16 0.568Elevated 5 25 30 24 53 25
LDH
Normal 16 84 68 14 0.076 62 15 0.291Elevated 3 16 0 0 33 27
Duration of symptoms<154 days (median) 11 55 76 16 0.188 76 16 0.463>154 days 9 45 29 22 51 20
Delay of chemotherapy<21 days 8 35 58 19 0.532 73 17 0.441>21 days 15 65 52 17 57 17
Timing of operation
After preoperative chemotherapy 18 78 52 14 0.929 64 13 0.587Primary surgery 5 22 67 27 67 27
Type of surgery
Resection 4 17 75 22 0.660 75 22 0.347Amputation 19 83 45 15 60 14
Surgical remission
Complete remission 21 95 60 13 0.000 72 12 0.000Macroscopic residual 2 9 0 0 0 0
Tumor response
Good 4 24 38 29 0.980 67 27 0.435Poor 13 76 64 15 59 16
5-year event-free and overall survival and P values in the log-rank test for all variables (see Data collection and Definition of Variables). SE! standard error;
P! two-sided P values.
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Our patients with osteosarcoma of the foot received the
same multimodal therapy including chemotherapy and
surgery as patients with osteosarcoma in general. While the
more frequent osteosarcomas of long extremity bones have
witnessed a major shift from amputation towards limb-
saving surgery over the past several decades [14], we did
not observe such a trend in this series, where three quarters
of all affected feet were either completely or partially
amputated.
Compared to osteosarcoma in general, where approxi-
mately half of all tumors respond well to preoperative
chemotherapy [13, 28, 33], only one quarter of 16 evaluable
pedal osteosarcomas from our series did so. We were not
able to extract information regarding response from other
published series, so that this disparity must probably be
considered a novel finding for which there is no immediate
explanation besides the small cohort size. The biology un-
derlying this apparent difference remains to be elucidated.
Like in extremity osteosarcoma in general [28], most
patients from our series achieved a first complete surgical
remission. The recurrence rate and the time to recurrence
were also similar to that which our group has observed for
extremity osteosarcoma in general [13, 34]. Interestingly,
there were no local recurrences as first event, a result which
may have been favored by the aggressive, mostly ablative
surgical approach employed. Given that wide margins may
be difficult to achieve by foot-salvaging procedures, margins
correlate with the local recurrence risk [35], prognosis
following local osteosarcoma recurrence is very poor [36]
and gait performance is often quite good following partial or
even complete amputation of the foot [37]; we believe that
such an aggressive surgical approach is well justified.
The recurrences we observed were mostly lung metas-
tases, again as well known for osteosarcoma in general
[28, 34]. Two patients had either primary or secondary
lymph node involvement, which is rather unusual for this
particular malignancy [30]. However, the small numbers
prohibit making definitive statements about whether the risk
for lymphatic spread is truly higher than for osteosarcomas
of other sites. Metastases in other published series were
usually pulmonary [1]. Nevertheless, we would recommend
careful assessment of the ipsilateral lymphatic drainage as
part of staging and follow-up of patients with an osteo-
sarcoma of the foot.
Given the very similar recurrence rates already discussed
above, it comes as no surprise that the 5-year event-free and
overall survival rates are also similar to those observed in
other series which included both localized and primary
metastatic osteosarcomas [14, 26, 38]. Even though tumor
size is a very well-established prognostic factor and osteo-
sarcomas of the foot are more likely to be detected at smaller
size, the obtained results are certainly not superior to those
our group has achieved in other long-bone extremity os-
teosarcomas [13]. We can only assume that this may be due
to a somewhat different tumor biology which also manifests
in the low response rate to preoperative chemotherapy. As
a note of caution, some papers on foot osteosarcomas have
reported higher cure rates, albeit based upon even smaller
patient numbers [4].
Patients with primary metastases are known to be as-
sociated with inferior event-free and overall survival rates
[13, 30, 39, 40], which was also seen in our cohort, where
none of the three patients with primary metastases survived.
Complete surgical remission, mostly achieved by amputa-
tion, was the strongest positive predictive factor for EFS and
OS in our cohort. In this context, we have to emphasize that
the subgroup of patients not receiving complete surgical
remission consisted of only 2 of the 23 patients and these
patients had inoperable primary metastases, respectively,
progressive disease under chemotherapy. Nonetheless, our
finding is in accordance with the general osteosarcoma
literature [13, 28]. When investigating other factors for
potential correlations with prognosis, such as tumor site
within the foot, size, elevated serum LDH or AP levels, or
response to preoperative chemotherapy [1, 13, 32, 41–43], we
did not observe significant correlations with either event-
free or overall survival, which may of course have been due
to the limited number of patients included in our study.
5. Conclusion
Our study is one of the largest cohorts of patients with
osteosarcoma of the foot reported to date despite the rela-
tively small collection of only 23 patients. Using the same
treatment strategy as employed in extremity osteosarcomas
in general, we also achieved similar results. Primary meta-
static status and surgical outcome correlated with prognosis.
These results argue in favor of treating osteosarcomas of the
foot like other extremity osteosarcomas and further high-
light the importance of achieving complete surgical re-
mission, especially regarding the poor response of the
tumors to neoadjuvant chemotherapy.
Disclosure
Peter Reichardt reports grants/personal fees from Novartis,
Pfizer Bayer, PharmaMar, Amgen, AstraZeneca, Clinigen,
Lilly, and Deciphera outside the submitted work; S. Bielack
reports grants from Deutsche Krebshilfe, Fo¨rderkreis kreb-
skranke Kinder Stuttgart e.V., and AXIS Forschungsstiftung
during the conduct of the study and from Lilly, Bayer, Pfizer,
Novartis, and Isofol outside the submitted work; Reinhard
Windhager reports grants from Boehringer Ingelheim, Pfizer,
Stryher, Taheda, and DePuy outside the submitted work. All
other authors disclose that they have no financial or personal
relationships with other people or organizations that could
inappropriately influence (bias) their work.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
The authors thank all patients who contributed to the
COSS studies and acknowledge the physicians, nurses, data
managers, and support staff of the collaborating centers for
their active participation and Joachim Gerß for his support
with the interpretation of survival analyses.Thanks are due
Sarcoma 9
to German Cancer Aid (Deutsche Krebshilfe) and spon-
sorship association for raising funds for children with cancer
Stuttgart (Fo¨rderkreis krebskranke Kinder Stuttgart e.V.) for
funding the work in question.
References
[1] J. K. Anninga, P. Picci, M. Fiocco et al., “Osteosarcoma of the
hands and feet: a distinct clinico-pathological subgroup,”
Virchows Archiv, vol. 462, no. 1, pp. 109–120, 2013.
[2] R. Biscaglia, A. Gasbarrini, T. Bo¨hling, P. Bacchini, F. Bertoni,
and P. Picci, “Osteosarcoma of the bones of the foot–an easily
misdiagnosed malignant tumor,” Mayo Clinic proceedings,
vol. 73, no. 9, pp. 842–847, 1998.
[3] H. M. Ozdemir, Y. Yildiz, C. Yilmaz, and Y. Saglik, “Tumors
of the foot and ankle: analysis of 196 cases,” Journal of Foot
and Ankle Surgery, vol. 36, no. 6, pp. 403–408, 1997.
[4] M. Brotzmann, F. Hefti, D. Baumhoer, and A. H. Krieg, “Do
malignant bone tumors of the foot have a different biological
behavior than sarcomas at other skeletal sites?,” Sarcoma,
vol. 2013, Article ID 767960, 8 pages, 2013.
[5] P. F. Choong, A. A. Qureshi, F. H. Sim, and K. K. Unni,
“Osteosarcoma of the foot: a review of 52 patients at the Mayo
Clinic,” Acta Orthopaedica Scandinavica, vol. 70, no. 4,
pp. 361–364, 1999.
[6] L. B. Chou, Y. Y. Ho, andM. M. Malawer, “Tumors of the foot
and ankle: experience with 153 cases,” Foot & Ankle In-
ternational, vol. 30, no. 9, pp. 836–841, 2009.
[7] R. Casadei, A. Ferraro, A. Ferruzzi, R. Biagini, and P. Ruggieri,
“Bone tumors of the foot: epidemiology and diagnosis,” La
Chirurgia degli Organi di Movimento, vol. 76, no. 1, pp. 47–62,
1991.
[8] R. Eyre, R. G. Feltbower, P.W. James et al., “The epidemiology
of bone cancer in 0-39 year olds in northern England,
1981–2002,” BMC Cancer, vol. 10, no. 1, p. 357, 2010.
[9] K. Winkler, G. Beron, G. Schellong et al., “Cooperative os-
teosarcoma study COSS-77: results after 4 years,” Klinische
Padiatrie, vol. 194, no. 4, pp. 251–256, 1982.
[10] K. Winkler, G. Beron, R. Kotz et al., “Neoadjuvant chemo-
therapy for osteogenic sarcoma: results of a Cooperative
German/Austrian study,” Journal of Clinical Oncology, vol. 2,
no. 6, pp. 617–624, 1984.
[11] K. Winkler, G. Beron, G. Delling et al., “Neoadjuvant che-
motherapy of osteosarcoma: results of a randomized co-
operative trial (COSS-82) with salvage chemotherapy based
on histological tumor response,” Journal of Clinical Oncology,
vol. 6, no. 2, pp. 329–337, 1988.
[12] N. Fuchs, S. S. Bielack, D. Epler et al., “Long-term results of
the co-operative German-Austrian-Swiss osteosarcoma study
group’s protocol COSS-86 of intensive multidrug chemo-
therapy and surgery for osteosarcoma of the limbs,” Annals of
Oncology, vol. 9, no. 8, pp. 893–899, 1998.
[13] B. S. S. Bielack, B. Kempf-bielack, G. U. Exner et al.,
“Prognostic factors in high-grade osteosarcoma of the ex-
tremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group pro-
tocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–
790, 2002.
[14] S. Bielack, H. Ju¨rgens, G. Jundt et al., “Osteosarcoma: the
COSS experience,” Cancer Treatment and Research, vol. 152,
no. 7, pp. 289–308, 2009.
[15] J. S. Whelan, S. S. Bielack, N. Marina et al., “EURAMOS-1, an
international randomised study for osteosarcoma: results
from pre-randomisation treatment,” Annals of Oncology,
vol. 26, no. 2, pp. 407–414, 2015.
[16] S. Bielack, S. Flege, and B. Kempf-Bielack, “Behand-
lungskonzept des osteosarkoms,” Der Onkologe, vol. 6, no. 8,
pp. 747–758, 2000.
[17] D. Carrle and S. S. Bielack, “Current strategies of chemo-
therapy in osteosarcoma,” International Orthopaedics, vol. 30,
no. 6, pp. 445–451, 2006.
[18] W. F. Enneking, S. S. Spanier, and M. A. Goodman, “Current
concepts review: the surgical staging of musculoskeletal
sarcoma,” Journal of Bone and Joint Surgery, vol. 62, no. 6,
pp. 1027–1030, 1980.
[19] M. Salzer-Kuntschik, G. Delling, G. Beron, and R. Sigmund,
“Morphological grades of regression in osteosarcoma after
polychemotherapy? Study COSS 80,” Journal of Cancer Re-
search and Clinical Oncology, vol. 106, no. S1, pp. 21–24, 1983.
[20] E. L. Kaplan and P. Meier, “Nonparametric estimation from
incomplete observations,” Journal of the American Statistical
Association, vol. 53, no. 282, pp. 457–481, 1958.
[21] N. Mantel, “Evaluation of survival data and two new rank
order statistics arising in its consideration,” Cancer Chemo-
therapy Reports, vol. 50, no. 3, pp. 163–170, 1966.
[22] D. R. Cox, “Regression models and life-tables,” Journal of the
Royal Statistical Society: Series B (Methodological), vol. 34,
no. 2, pp. 187–220, 1972.
[23] F. Wilcoxon, “Individual comparisons of grouped data by
ranking methods,” Journal of Economic Entomology, vol. 39,
no. 6, pp. 269-270, 1946.
[24] G. Gatta, R. Capocaccia, C. Stiller, P. Kaatsch, F. Berrino, and
M. Terenziani, “Childhood cancer survival trends in Europe:
a EUROCARE working group study,” Journal of Clinical
Oncology, vol. 23, no. 16, pp. 3742–3751, 2005.
[25] C. A. Stiller, S. S. Bielack, G. Jundt, and E. Steliarova-Foucher,
“Bone tumours in European children and adolescents,
1978–1997: report from the Automated Childhood Cancer
Information System project,” European Journal of Cancer,
vol. 42, no. 13, pp. 2124–2135, 2006.
[26] L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma
incidence and survival rates from 1973 to 2004: data from the
surveillance, epidemiology, and end results program,” Cancer,
vol. 115, no. 7, pp. 1531–1543, 2009.
[27] G. Gatta, L. Botta, S. Rossi et al., “Childhood cancer survival in
Europe 1999-2007: Results of EUROCARE-5-a population-based
study,” The Lancet Oncology, vol. 15, no. 1, pp. 35–47, 2014.
[28] G. Bacci, A. Longhi, M. Versari, M. Mercuri, A. Briccoli, and
P. Picci, “Prognostic factors for osteosarcoma of the extremity
treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution,” Cancer, vol. 106,
no. 5, pp. 1154–1161, 2006.
[29] L. Kager, A. Zoubek, U. Kastner et al., “Skip metastases in
osteosarcoma: experience of the Cooperative Osteosarcoma
Study Group,” Journal of Clinical Oncology, vol. 24, no. 10,
pp. 1535–1541, 2006.
[30] L. Kager, A. Zoubek, U. Po¨tschger et al., “Primary metastatic
osteosarcoma: presentation and outcome of patients treated
on neoadjuvant Cooperative Osteosarcoma Study Group
protocols,” Journal of Clinical Oncology, vol. 21, no. 10,
pp. 2011–2018, 2003.
[31] H.-Y. Ren, L.-L. Sun, H.-Y. Li, and Z.-M. Ye, “Prognostic
significance of serum alkaline phosphatase level in osteo-
sarcoma: a meta-analysis of published data,” BioMed Research
International, vol. 2015, Article ID 160835, 11 pages, 2015.
[32] G. Bacci, A. Longhi, S. Ferrari et al., “Prognostic significance
of serum lactate dehydrogenase in osteosarcoma of the
10 Sarcoma
extremity: experience at Rizzoli on 1421 patients treated over
the last 30 years,” Tumori, vol. 90, no. 5, pp. 478–484, 2004.
[33] J. S. Whelan, R. C. Jinks, A. McTiernan et al., “Survival from
high-grade localised extremity osteosarcoma: combined re-
sults and prognostic factors from three European osteosar-
coma intergroup randomised controlled trials,” Annals of
Oncology, vol. 23, no. 6, pp. 1607–1616, 2012.
[34] B. Kempf-Bielack, S. S. Bielack, H. Ju¨rgens et al., “Osteo-
sarcoma relapse after combined modality therapy: an analysis
of unselected patients in the Cooperative Osteosarcoma Study
Group (COSS),” Journal of Clinical Oncology, vol. 23, no. 3,
pp. 559–568, 2005.
[35] P. Picci, S. Ferrari, G. Bacci, and F. Gherlinzoni, “Treatment
recommendations for osteosarcoma and adult soft tissue
sarcomas,” Drugs, vol. 47, no. 1, pp. 82–92, 1994.
[36] S.Weeden, R. J. Grimer, S. R. Cannon et al., “The effect of local
recurrence on survival in resected osteosarcoma,” European
Journal of Cancer, vol. 37, no. 1, pp. 39–46, 2001.
[37] R. Versluys, A. Desomer, G. Lenaerts et al., “From conven-
tional prosthetic feet to bionic feet: a review study,” in Pro-
ceedings of the 2nd IEEE RAS & EMBS International
Conference on Biomedical Robotics and Biomechatronics,
pp. 49–54, Scottsdale, AZ, USA, October 2008.
[38] M. T. Harting, K. P. Lally, R. J. Andrassy et al., “Age as
a prognostic factor for patients with osteosarcoma: an analysis
of 438 patients,” Journal of Cancer Research and Clinical
Oncology, vol. 136, no. 4, pp. 561–570, 2010.
[39] G. Bacci, M. Rocca, M. Salone et al., “High-grade osteosar-
coma of the extremities with lung metastases at presentation:
treatment with neoadjuvant chemotherapy and simultaneous
resection of primary and metastatic lesions,” Journal of
Surgical Oncology, vol. 98, no. 6, pp. 415–420, 2008.
[40] M. San-Julian, P. Diaz-de-Rada, E. Noain, and L. Sierrasesumaga,
“Bone metastases from osteosarcoma,” International Ortho-
paedics, vol. 27, no. 2, pp. 117–120, 2003.
[41] P. Bieling, N. Rehan, P. Winkler et al., “Tumor size and
prognosis in aggressively treated osteosarcoma,” Journal of
Clinical Oncology, vol. 14, no. 3, pp. 848–858, 1996.
[42] S. K. Min, S. Y. Lee, H. C. Wan et al., “Initial tumor size
predicts histologic response and survival in localized osteo-
sarcoma patients,” Journal of Surgical Oncology, vol. 97, no. 5,
pp. 456–461, 2008.
[43] E. Gonza´lez-Billalabeitia, R. Hitt, J. Ferna´ndez et al., “Pre-
treatment serum lactate dehydrogenase level is an important
prognostic factor in high-grade extremity osteosarcoma,”
Clinical and Translational Oncology, vol. 11, no. 7, pp. 479–
483, 2009.
Sarcoma 11
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
???????????????????????????????
?????????????????????? ????????????? ??? ??
??????????????
?????????????
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
